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Long-term effects on bone mineral density of pamidronate degree of bone loss and the site at which bone is lost is
given at the time of renal transplantation. affected by gender [3]. Renal transplant patients have
Background. Fracture rate after renal transplantation is sub-
also been documented to have bone fracture rates threestantially increased, is a source of morbidity and mortality, and
times higher than comparable dialysis patients [4]. As manycorrelates with osteopenia. The rate of bone loss after trans-
plantation is time dependent. While we recorded marked bone as 40% of patients with type I diabetes mellitus suffer
loss during the first year after renal transplantation, bone loss a bone fracture within 3 years of renal transplantation [5].
in long-term recipients (24 months) was found to be similar
While bone mineral density (BMD) is a good predictor ofto expected age-related decline. We have previously shown
fracture risk in postmenopausal women, this is less clearthat treatment with pamidronate at the time of transplantation
protected the skeleton over a 1-year study period. in other causes of secondary osteoporosis. However, Grotz
Methods. We have reexamined patients who participated in et al [4] have found that this correlation exists in renalour original study, all of whom had been randomized to receive
transplant patients. The cause of bone loss in the immedi-either placebo or pamidronate (0.5 mg/kg) at the time of trans-
plantation and 1 month later. We now report 4-year data from ate posttransplant period is likely to be multifactorial,
17 of the 26 original cohort. All patients received immunosup- including the effects of immunosuppression (particularly
pression, comprising prednisolone, cyclosporine, and azathio-
glucocorticoids and calcineurin inhibitors [6]) and immo-prine.
bility superimposed on preexisting renal osteodystrophyResults. We found that without prophylaxis bone loss at 4
years was substantial and significant at the femoral neck (mean [2]. Moreover, even in patients with excellent graft func-
loss was 12.3%) but was not significant at the lumbar spine tion, hyperparathyroidism has been found to persist for
(mean loss was 4.64%). Patients who received two doses of
a considerable time and sometimes indefinitely.pamidronate experienced no statistically significant bone loss
at either the femoral neck or the lumbar spine. Patient charac- In a prospective randomized trial [7], we found that
teristics of the placebo and treatment groups were similar with in male transplant recipients without prophylaxis, bone
the exception of serum parathyroid hormone concentrations, loss 12 months after transplantation was 9.0% at the femo-which remained higher at 4 years in the pamidronate-treated
ral neck and 6.4% at the lumbar spine. Patients random-patients (15.8  3.7 pmol/L vs. 9.8  1.8 pmol/L, P  0.05).
Conclusion. Without prophylaxis, most patients who con- ized to receive two doses of pamidronate (0.5 mg/kg),
tinue to receive low dose glucocorticoids as part of maintenance given intravenously at the time of transplantation and at
immunosuppression manifest a substantial deficit in bone min-
1 month, experienced no statistically significant bone losseral density (BMD) at the femoral neck. In contrast, two doses
at 12 months at either the femoral neck or the lumbarof pamidronate given at the time of transplantation and 1
month later protected the skeleton from significant bone loss spine. Similar protection against early bone loss has since
over the 4 years after transplantation. been shown with ibandronate [8]. Moreover, Grotz et al
[9] have documented that bone loss 24 months after
transplantation is no greater than the expected age- andRecipients of renal and other solid organ transplants
gender-dependent decline. It is, therefore, possible thatexperience rapid bone loss during the first year after trans-
early bone protection can provide sufficient long-termplantation [1, 2] and we have previously shown that the
protection against osteoporosis in many transplant pa-
tients.
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In an attempt to define the extent of long-term protec-nate, renal, control trial.
tion provided by treatment with pamidronate at the time
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Table 1. Clinical details measured using a DAX autoanalyzer (Bayer Diagnos-
tics, Basingstoke, UK). Plasma cyclosporine concentra-Pamidronate Control
tions were measured by a monoclonal cyclosporine-spe-Number of patients 9 8
Age at time of transplantation cific radioimmunoassay (Incstar, Stillwater, MN, USA).
range 46.2 (21.1–67.1) 41.5 (21.3–65.0) PTH was measured by two-site radioimmunoassays for
Modality at time of trans-
intact PTH supplied by Diagnostic Product Corp., Losplantation (hemodialysis:
continuous ambulatory Angeles, CA, USA. At the time of transplantation, the
peritoneal dialysis) 2:7 5:3 Immulite assay was used, while repeat PTH estimationsTime on dialysis years 3.6 (1.7) 4.0 (2.1)
at 4 years were measured using the poly-poly ImmuliteNumber with diabetes mellitus 0 0
Etiology of renal failure 2000 that used the same polyclonal antibodies. The nor-
Chronic glomerulonephritis 1 2 mal ranges for these assays were 10 to 65 pg/mL and 1.1APKD 4 4
to 6.8 pmol/L, respectively. Intra-assay and interassayHypertension 1 0
Vasculitis 1 1 coefficient of variations were less than 7% in the range
Dysplastic kidneys 1 0 of our patients’ results.Unknown/others 1 1
Bone densitometry
DXA was performed using a Lunar DPX scanner
METHODS (Lunnar Radiation Corp., Madison, WI, USA). We mea-
sured BMD at the second, third, and fourth lumbar verte-We originally studied 26 male patients admitted for
renal transplantation. Of the 14 patients who were ran- brae in the anterior-posterior projection (L2-4) and at
domized to receive pamidronate prophylaxis, nine un- the femoral neck. In-house precision of these measure-
derwent a dual energy x-ray absorpiometry (DXA) scan ments was 2% for all indices. BMD was expressed
4 years after transplantation. One patient returned to in g/cm2, calibrated against calcium hydroxapatite and
hemodialysis within 12 months, three died, and one de- reproducibility of repeated measurements using the ma-
clined to have a repeat DXA scan. Of the original 12 chine was also 2%. The results were compared with
patients who were randomized to receive placebo (500 mL the United Kingdom reference database (age/gender
of 0.9% saline), eight patients underwent a DXA at matched) to generate a T score.
4 years. Again, one patient died, one was transferred to
Statistical analysisanother hospital, one returned to hemodialysis, and one
patient declined to have a repeat DXA scan. The details Paired Student t tests (two-tailed) were used to com-
of the enrolled patients are listed in Tables 1 and 2. pare intragroup changes of the regional BMD. Regres-
sion analysis was used to relate serum PTH concentra-Study protocol
tions to the changes in BMD. P values of less than 0.05
Patients assigned to receive pamidronate had an intra- (two-tailed) were considered to indicate statistical sig-
venous infusion of 0.5 mg/kg in 500 mL 0.9% saline nificance.
peroperatively and 1 month postoperatively. The control
patients did not receive any prophylaxis against bone
loss. Both groups received standard immunosuppression RESULTS
with cyclosporine, azathioprine, and prednisolone (Ta- Serum biochemistry
ble 3). Episodes of renal dysfunction were managed con-
At the time of transplantation, both pamidronate andventionally by renal biopsy and treatment of confirmed
control patients had similar serum PTH concentrationsrejection with three 500 mg doses of methylprednisolone.
(30.6  9.4 pmol/L vs. 21.9  7.9 pmol/L, respectively,None of these patients required biologic agents for im-
P  NS), serum alkaline phosphatase, and calcium con-munosuppression. DXA scans were performed in the
centrations (Table 2). At 4 years, there was no statisti-first week of transplantation and at 4 years. Serum intact
cally significant difference in mean serum creatinine con-parathyroid hormone (PTH) concentrations were mea-
centrations between pamidronate and control patientssured preoperatively and at 4 years. Routine blood chem-
(180 18mol/L vs. 138 9.5mol/L, respectively, Pistries, including calcium, phosphate, and total alkaline
NS). In addition, there were no significant differencesphosphatase concentration, were measured daily for 2
in the mean serum calcium and alkaline phosphataseweeks and thereafter at frequencies dictated by clinical
concentrations between the two groups. However, theevents.
mean 4-year serum PTH concentration in the pamidro-
Laboratory measurements nate group of patients was significantly higher than in
the control patients (15.8  2.1 pmol/L vs. 9.8  1.8Routine blood chemistries, including calcium (adjusted
for albumin), alkaline phosphatase, and creatinine, were pmol/L, resepectively, P  0.05 by Student t test).
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Table 2. Biochemistry
Pamidronate (N  9) Control (N  8)
Serum concentration Pretransplant 1 year 4 years Pretransplant 1 year 4 years
Creatinine lmol/L 160 (6) 180 (18) 148 (17.0) 138 (9.5)
iPTH pmol/L 30.6 (9.4) 11.5 (2.8)a 15.8 (2.13)a 21.8 (8.1) 9.2 (1.9)a 9.8 (1.8)a,b
Calcium mmol/L 2.42 (0.11) 2.38 (0.05) 2.38 (0.05) 2.41 (0.10) 2.41 (0.04) 2.46 (0.03)
Alkaline phosphatase IU/L 86.4 (12.1) 62.4 (9.9) 55.2 (7.0) 67.9 (10.1) 72.4 (8.5) 57.6 (6.1)
aP  0.05 vs. pretransplant values; bP  0.05 vs. 4-year pamidronate group
Table 3. Immunosuppression protocol
Cyclosporine Azathioprin Prednisolone
mg/kg/day mg/kg/day mg/day
Day 1 10 2 80
Day 2 and 3 8 2 20
Day 4 to week 4 Titrate dose to serum 2 20
Weeks 4–8 concentration of: 2 15
Weeks 8–12 200–250 g/L 2 10
Week 12 to month 12 150–200 g/L 2 10
After 1 year 100–150 g/L 2 10
Rejection and immunosuppression with the 4-year femoral neck BMD or the change in
femoral neck BMD.A total of 15 episodes of acute rejection were diag-
Control patients experienced a significant reductionnosed and treated. Five patients in the pamidronate
of lumbar spine BMD at 1 year (baseline BMD 1.27 group received a total of eight courses of pulsed methyl-
0.07 g/cm2 while 1-year BMD was 1.20 0.05 g/cm2, Pprednisolone, while six patients in the control group suf-
0.05). This was not seen in pamidronate-treated patientsfered a total of seven episodes of acute rejection. Gluco-
(baseline BMD 1.15  0.07 g/cm2 vs. 1.11  0.05 g/cm2corticoids were not withdrawn in any patients in either
at one year, P  NS). At 4 years, neither the control norgroup. The mean dose of prednisolone prescribed to the
the pamidronate group of patients showed statisticallypamidronate group of patients was 8.9  0.4 mg/day vs.
significant reductions in lumbar spine BMD from base-7.8 0.8 mg/day (PNS) for the control patients. Mean
line (BMD at 4 years was 1.21 0.08 g/cm2 in the controlblood cyclosporine concentrations at 4 years were similar
and 1.10  0.04 g/cm2 in the treatment groups) (Fig.in the pamidronate and control patients (151  12 g/L
1B). Neither the initial nor 4-year PTH concentrationvs. 132  6.6 g/L, P  NS).
correlated with the 4-year lumbar spine BMD or the
Bone mineral density change in lumbar spine BMD.
At the femoral neck, significant reduction of BMD
was found in the control patients at 1 and 4 years post
DISCUSSIONtransplantation (Fig. 1A). The mean BMD was 1.08 
Adverse skeletal outcomes after renal transplantation0.07 g/cm2 at the time of transplantation, falling to a
and measures to prevent them remain a matter of intensemean BMD of 0.98  0.06 g/cm2 at 1 year (P  0.005)
interest [10]. We have previously shown that two dosesand 0.94  0.06 g/cm2 at 4 years (P  0.01). The mean
of pamidronate, given at the time of renal transplantationpercentage reduction of BMD over 1 and 4 years were
and 1 month later, can protect the skeleton from early8.8  2.2% and 12.3  2.8%, respectively. In these con-
bone loss [7]. Grotz et al [8] studied the effects of iban-trol patients, five of eight patients experienced 10%
dronate given at three monthly intervals during the firstreduction of BMD at the femoral neck. In contrast, the
year after renal transplantation and showed similar early4-year femoral neck BMD of patients who received pam-
protection against bone loss. They also showed a reduc-idronate was not significantly different from baseline.
tion of spinal deformation. However, issues regardingBMD at baseline was 0.93  0.05 g/cm2, at 1 year it was
the appropriate duration of prophylaxis and identifica-0.94  0.04 g/cm2, and at 4 years it was 0.88  0.04 g/cm2,
tion of patients requiring prolonged therapy remain un-P  NS (Fig. 1A). However, three patients experienced
resolved.bone loss 10% (10.9%, 13.5%, and –16.2%). Nei-
ther the initial nor 4-year PTH concentration correlated We have now demonstrated that early prophylaxis
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4-year PTH concentration correlated with bone loss or
absolute BMD at either site measured. Although this
may seem counter intuitive, a correlation between PTH
and bone loss after transplantation has only been found
in one study and was limited to women [3].
The pathogenesis of posttransplant osteoporosis is
multifactorial. Bone histomorphometry at 6 months after
renal transplantation was compatible with the toxic ef-
fect of glucocorticoids [1]. Moreover, calcineurin inhibi-
tors and persisting hyperparathyroidism are known to in-
crease bone resorption. However, Monier-Faugere et al
[11] have recently shown that the majority of patients
after renal transplantation have both generalized and
focal osteomalacia on bone biopsy. Carlini et al [12] also
showed similar bone pathologies, but encouragingly the
abnormalities of bone formation rate and mineralization
improved with time and approached normal after ap-
proximately 10 years. These findings have raised the
possibility that prolonged treatment with bisphospho-
nates with extended biologic activity might further re-
duce bone turnover and potentially increase morbidity.
It is, therefore, important to ascertain if bone loss contin-
ues at a high rate after the initial 12 months posttrans-
Fig. 1. Effect of renal transplantation on bone mineral density (BMD) plantation.
at (A) femoral neck and (B) lumbar spine. Individual patient’s BMD Results from this and our previous study [7] showedare shown in dashed gray lines and mean (SEM) BMD are shown in
that the high rate of bone attrition at the femoral necksolid black lines. *P  0.005.
during the first few months slows thereafter (equivalent
to 20% per annum at 3 months, 9% per annum at 12
months, and 3% per annum at 4 years). This contrasts
with two doses of pamidronate not only prevented statis- with the bone loss that is experienced by women during
tically significant loss of BMD at the femoral neck and
menopause which is much slower at 1% to 2% per year.
the lumbar spine at 1 year after renal transplantation
However, there was wide variation in bone loss whether
[7], but also provided sustained protection at the femoral
or not patients received pamidronate. One third of theneck up to 4 years after transplantation. By contrast,
pamidronate-treated patients lost 10% BMD at thepatients who did not receive pamidronate lost a statisti-
femoral neck over the 4-year study period. Thus, contin-cally significant amount of bone at the femoral neck at
ued vigilance of patients’ BMD is necessary to identify1 and 4 years (mean loss was 8.8  2.2% and 12.3 
those who might benefit from continued treatment. Such2.8% respectively). The BMD at the lumbar spine of
a strategy minimizes the number of patients exposedcontrol patients fell significantly 1 year after transplanta-
long-term to the potential deleterious effects of bisphos-tion (mean loss was 5.2 2.4%) but appeared to recover
phonates, a concern as osteomalacic lesions are presentat 4 years such that there was no statistical difference in
in many posttransplant patients [11]. It is encouragingBMD compared with baseline. Although controlled, this
to find that for the majority of patients, the two-dosestudy was small and of low power. However, it provides
pamidronate regimen was well tolerated and appears tothe first insight into the long-term action of bisphospho-
provide considerable long-term skeletal protection.nates following renal transplantation.
A major limitation of this study is that it is poweredIn this study, the mean 4-year PTH concentration was
to only examine intragroup changes in BMD within pa-significantly higher in the pamidronate group than the
tients who did or did not receive pamidronate after trans-controls. Although PTH can be anabolic to bone under
plantation but was not designed nor powered to examinecertain conditions (particularly if administered in a pul-
the effects of bisphosphonates at reducing the bone frac-satile manner) and a license for PTH as a treatment
ture rates or bone histomorphometry. Larger studiesof osteoporosis has been sought in the United States,
powered to examine clinical end points directly are re-sustained hyperparathyroidism increases bone resorp-
quired to define further how we should monitor and treattion and is an important cause of secondary osteoporosis.
However, in this study, neither the pretransplant nor the patients after renal and other solid organ transplants.
Fan et al: Long-term effect of pamidronate 2279
Reprint requests to Dr. Stanley L-S. Fan, The Department of Renal in diabetes mellitus and females after renal transplantation. Trans-
plantation 67:1218–1222, 1999Medicine and Transplantation, The Royal London Hospital, White-
6. Movsowitz C, Epstein S, Fallon M, et al: Cyclosporin A in vivochapel, London E1 1BB, United Kingdom.
produces severe osteopenia in the rat. Effect of dose and durationE-mail: fan.stanley@bartsandthelondon.nhs.uk
of administration. Endocrinology 123:2571–2577, 1988
7. Fan SL-S, Almond MK, Ball E, et al: Pamidronate therapy as
REFERENCES prevention of bone loss following renal transplantation. Kidney
Int 57:684–690, 2000
1. Julian BA, Laskow DA, Dubovsky J, et al: Rapid loss of verebral 8. Grotz W, Nagel C, Poeschel D, et al: Effect of ibandronate on
mineral density after renal transplantation. N Engl J Med 325:544– bone loss and renal function after kidney transplantation. J Am
550, 1991 Soc Nephrol 12:1530–1537, 2001
2. Kwan JT, Almond MK, Evans K, Cunningham J: Changes in 9. Grotz WH, Mundinger FA, Rasenack J, et al: Bone loss after
total body bone mineral content and regional bone mineral density kidney transplantation: A longitudinal study in 115 graft recipients.
in renal patients following renal transplantation. Miner Electrolyte Nephrol Dial Transplant 10:2096–2100, 1995
Metab 18:166–168, 1992 10. Fan SL, Cunningham J: Bisphosphonates in renal osteodystrophy.
3. Almond MK, Kwan JT, Evans K, Cunningham J: Loss of regional Curr Opin Nephrol Hypertens 10:581–588, 2001
bone mineral density in the first 12 months following renal trans- 11. Monier-Faugere MC, Mawad H, Qi Q, et al: High prevalence of
plantation. Nephron 66:52–57, 1994 low bone turnover and occurrence of osteomalacia after kidney
4. Grotz WH, Mundinginger FA, Gugel B, et al: Bone fracture transplantation. J Am Soc Nephrol 11:1093–1099, 2000
and osteodensitometry with dual energy x-ray absorpiometry in 12. Carlini RG, Rojas E, Weisinger JR, et al: Bone disease in patients
kidney transplant recipients. Transplantation 58:912–915, 1994 with long-term renal transplantation and normal renal function.
Am J Kidney Dis 36:160–166, 20005. Nisbeth U, Lindh E, Ljunghall S, et al: Increased fracture rate
